JP2013056901A5 - - Google Patents

Download PDF

Info

Publication number
JP2013056901A5
JP2013056901A5 JP2012231759A JP2012231759A JP2013056901A5 JP 2013056901 A5 JP2013056901 A5 JP 2013056901A5 JP 2012231759 A JP2012231759 A JP 2012231759A JP 2012231759 A JP2012231759 A JP 2012231759A JP 2013056901 A5 JP2013056901 A5 JP 2013056901A5
Authority
JP
Japan
Prior art keywords
ethanol
propanol
iso
solution
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012231759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013056901A (ja
JP5726833B2 (ja
Filing date
Publication date
Priority claimed from US11/330,868 external-priority patent/US8436190B2/en
Application filed filed Critical
Publication of JP2013056901A publication Critical patent/JP2013056901A/ja
Publication of JP2013056901A5 publication Critical patent/JP2013056901A5/ja
Application granted granted Critical
Publication of JP5726833B2 publication Critical patent/JP5726833B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

JP2012231759A 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物 Active JP5726833B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64435405P 2005-01-14 2005-01-14
US60/644,354 2005-01-14
US11/330,868 US8436190B2 (en) 2005-01-14 2006-01-12 Bendamustine pharmaceutical compositions
US11/330,868 2006-01-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007551416A Division JP2008526991A (ja) 2005-01-14 2006-01-13 ベンダムスチン製薬学的組成物

Publications (3)

Publication Number Publication Date
JP2013056901A JP2013056901A (ja) 2013-03-28
JP2013056901A5 true JP2013056901A5 (enExample) 2015-04-09
JP5726833B2 JP5726833B2 (ja) 2015-06-03

Family

ID=36678237

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007551416A Pending JP2008526991A (ja) 2005-01-14 2006-01-13 ベンダムスチン製薬学的組成物
JP2012231759A Active JP5726833B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物
JP2012231760A Active JP5688195B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007551416A Pending JP2008526991A (ja) 2005-01-14 2006-01-13 ベンダムスチン製薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012231760A Active JP5688195B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物

Country Status (19)

Country Link
US (9) US8436190B2 (enExample)
EP (2) EP2574334A1 (enExample)
JP (3) JP2008526991A (enExample)
KR (4) KR101648495B1 (enExample)
CN (1) CN102078305B (enExample)
AR (1) AR052877A1 (enExample)
AU (1) AU2006204817B2 (enExample)
BR (1) BRPI0606332A2 (enExample)
CA (1) CA2593582A1 (enExample)
EA (1) EA013324B1 (enExample)
ES (1) ES2405611T3 (enExample)
IL (1) IL184394A0 (enExample)
MX (1) MX2007008562A (enExample)
MY (1) MY157661A (enExample)
NO (1) NO343659B1 (enExample)
NZ (1) NZ556435A (enExample)
SG (1) SG158870A1 (enExample)
TW (1) TWI380830B (enExample)
WO (1) WO2006076620A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
ES2583804T3 (es) * 2007-10-09 2016-09-22 Us Worldmeds Llc Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
AU2009234277B2 (en) * 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
JP2012508749A (ja) * 2008-11-13 2012-04-12 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 多発性骨髄腫治療のためのベンダムスチン、ドキソルビシンおよびボルテゾミブの併用
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
HRP20140204T1 (hr) * 2008-12-03 2014-04-11 Astellas Deutschland Gmbh Oralni oblici doziranja bendamustina
MX2011007557A (es) * 2009-01-15 2011-08-12 Cephalon Inc Formas nuevas de bendamustina como base libre.
PT2389375E (pt) 2009-01-23 2015-09-17 Euro Celtique Sa Derivados de ácido hidroxâmico
RU2591804C2 (ru) * 2009-02-25 2016-07-20 Супратек Фарма, Инк. Композиции бендамустина и циклополисахарида
CN102413816A (zh) * 2009-04-28 2012-04-11 赛福伦公司 苯达莫司汀的口服制剂
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
EP3895694A1 (en) 2010-01-28 2021-10-20 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
DK2575784T3 (en) * 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
MX2013000373A (es) * 2010-07-13 2013-02-15 Cephalon Inc Metodos mejorados para la esterilizacion de bendamustina.
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP2667868A4 (en) * 2011-01-25 2014-12-10 Reddys Lab Ltd Dr Benda MUSTIN FORMULATIONS
AU2012214419B2 (en) * 2011-02-09 2015-12-24 Glaxosmithkline Llc Lyophilized formulations
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
WO2013039488A1 (en) * 2011-09-13 2013-03-21 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
WO2013102920A1 (en) 2011-11-18 2013-07-11 Astron Research Limited Stable lyophilized formulation of bendamustine
WO2013112762A1 (en) * 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
AR092790A1 (es) * 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
US9872873B2 (en) 2012-02-06 2018-01-23 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
JP2015506989A (ja) * 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
RS58744B1 (sr) 2012-03-20 2019-06-28 Eagle Pharmaceuticals Inc Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje
WO2013148919A1 (en) 2012-03-30 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment of multiple myeloma
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
MX2015005805A (es) 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.
EP2732811B1 (de) 2012-11-19 2016-01-13 Oncotec Pharma Produktion GmbH Verfahren zur Herstellung einer gefriergetrockneten Zusammensetzung
CN103860482B (zh) * 2012-12-12 2016-08-24 海口市制药厂有限公司 一种盐酸苯达莫司汀冻干粉针剂的制备方法、其产品及用途
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
WO2014127802A1 (en) 2013-02-19 2014-08-28 Synthon Bv Stable compositions of bendamustine
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
ITMI20131013A1 (it) 2013-06-19 2014-12-20 Chemi Spa Formulazioni liofilizzate di bendamustina cloridrato
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
CN103351347A (zh) * 2013-07-29 2013-10-16 东南大学 盐酸苯达莫司汀杂质dce的制备方法
JP6571657B2 (ja) * 2013-08-27 2019-09-04 ボウドウリス バシリオス ベンダムスチンの薬学的組成物
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
WO2015054550A1 (en) * 2013-10-11 2015-04-16 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
IN2014CH00151A (enExample) * 2014-01-13 2015-07-17 Hetero Research Foundation
CN106102722A (zh) * 2014-03-13 2016-11-09 V·沃道里斯 苯达莫司汀固体分散体和连续输液
WO2015171460A2 (en) 2014-05-09 2015-11-12 AuroMedics Pharma LLC Formulations of cyclophosphamide liquid concentrate
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) * 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
AU2016349516A1 (en) * 2015-11-04 2018-05-31 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
EP3836921B1 (en) 2018-08-17 2025-10-08 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
CA3124001A1 (en) 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating lymphoma or a t-cell malignant disease
US11406598B2 (en) 2019-09-20 2022-08-09 Nivagen Pharmaceuticals, Inc. Lyophilized compositions of phenobarbital sodium salt
CN110638765A (zh) * 2019-11-08 2020-01-03 江苏食品药品职业技术学院 一种卡莫司汀冻干工艺
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
DE80967C (enExample)
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DE1354952U (enExample)
DD80967A (enExample)
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
DE58900183D1 (de) 1988-03-19 1991-08-29 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PT725642E (pt) * 1993-10-27 2000-05-31 Upjohn Co Prostaglandina e 1 estabilizada
US5561121A (en) * 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
AU699272B2 (en) * 1994-08-02 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
EP0859779A4 (en) 1995-08-31 2000-04-12 Smithkline Beecham Corp INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ATE315392T1 (de) * 1998-07-09 2006-02-15 Francis A Nardella Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR20040025880A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 수용해성이 개선된 의약 조성물
EP1350793A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
EP1435877B1 (de) * 2001-10-15 2009-04-15 Hemoteq AG Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ATE389183T1 (de) 2002-03-22 2008-03-15 Univ Muenchen L Maximilians Zytokapazität-verfahren
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
MXPA04011111A (es) 2002-05-09 2005-07-14 Hemoteq Gmbh Productos medicos que comprenden un revestimiento hemocompatible, produccion y uso de los mismos.
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
CA2504283A1 (en) 2002-10-31 2004-05-21 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1594900A2 (en) * 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5670335B2 (ja) 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤

Similar Documents

Publication Publication Date Title
JP2013056901A5 (enExample)
Shah et al. Melt extrusion with poorly soluble drugs
PH12015502290A1 (en) Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
JP2014129360A5 (enExample)
BR112012024683A2 (pt) preparado sólido facilmente dosável
IN2012DE00337A (enExample)
WO2014118808A3 (en) Ticagrelor solid dispersion
PE20110583A1 (es) Comprimidos de capecitabina de disgregacion rapida
AR094936A1 (es) Suspensión para administración oral que comprende tolvaptán amorfo, y a un método para producirla
BR112014030160A2 (pt) composição formadora de película, uso de uma composição formadora de película, película e cápsula dura
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
JP2013525485A5 (enExample)
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
HK1212978A1 (zh) 芥子酸的新型衍生物
RU2012110454A (ru) Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в интерфероне
EA201591860A1 (ru) Усилители водорастворимости на основе гликогена
RU2015130495A (ru) Композиция кабазитаксела
JP2016508138A5 (enExample)
JP2016522257A5 (enExample)
ES2441468B1 (es) Composición farmacéutica sólida de resina de intercambio catiónico.
CR20140355A (es) Formulaciones de antibióticos
CO6331424A2 (es) Formulacion farmaceutica de eprosartan
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo